. 2021 Jan 12;12(1):e03134-20. doi: 10.1128/mBio.03134-20

TABLE 3.

Information on study participants failing a RAL-containing regimen

PID^a	Sample collection^b		HIV-1 RNA (copies/ml)	RAL conc. (ng/ml)	IN accessory/resistance mutation(s) (%)^c
PID^a	Time point	Day	HIV-1 RNA (copies/ml)	RAL conc. (ng/ml)	IN accessory/resistance mutation(s) (%)^c
A1	Pre-ART	0	805,710		No mutations detected
	Early RAL failure	181	570	990	Not determined
	Late RAL failure	250	11,335	89	T97A (33), N155H (5.6)
A2	Pre-ART	0	17,450		No mutations detected
A2	Late RAL failure	195	1,772	93	No mutations detected
A3	Pre-ART	0	1,329,415		No mutations detected
	Early RAL failure	178	433	965	Not determined
	Late RAL failure	196	1,139	3,371	F121Y (14)
A4	Pre-ART	0	1,617,523		No mutations detected
	Early RAL failure	175	7,208	1,142	E138K (2.7), N155H (73)
	Late RAL failure	199	9,918	480	Not determined
A5	Pre-ART	0	30,206		No mutations detected
A5	Late RAL failure	194	18,806	2,729	G163K (4.8)

PID, participant identifier.

Samples are derived from the SELECT study (5).

RAL resistance mutations are indicated in boldface font.